Literature DB >> 26453528

Anemia and its association with clinical outcome in heart failure patients undergoing cardiac resynchronization therapy.

Ramkumar V Venkateswaran1, Carolyn Freeman2, Neal Chatterjee2, Jagdesh Kandala2, Mary Orencole2, Eszter M Vegh2, Kimberly A Parks2, Peter J Cowburn3, G William Dec1,2, Jagmeet P Singh2, Rasmus Borgquist4,5.   

Abstract

PURPOSE: Although a substantial proportion of patients with heart failure (HF) have anemia, there is a paucity of data evaluating the impact of anemia on clinical outcome in CRT patients. Our goal was to examine the ability of baseline hemoglobin (Hb) level and change in Hb level over time to predict clinical 2-year outcome and echocardiographic response to CRT.
METHODS: Three hundred consecutive CRT patients (median 72 years [interquartile range (IQR) 16 years], 19% female) with baseline and follow-up hematological profiles available were examined. Baseline anemia was defined as Hb <12 g/dL in women and <13 g/dL in men, and patients were grouped into equal quartiles based on change in Hb. Two-year clinical outcome was determined using a composite endpoint that included HF hospitalization, left ventricular assist device (LVAD) placement, heart transplantation, and all-cause mortality. Echocardiographic reverse remodeling was examined at 6-month follow-up.
RESULTS: One hundred fifty-one anemic patients were compared to 149 non-anemic patients. Changes in left ventricular dimensions and ejection fraction were similar for both groups. Univariate predictors of 2-year clinical outcome included baseline creatinine level, diuretic usage, and anemia; in multivariable regression, baseline anemia was an independent predictor for outcome (hazard ratio [HR] 1.79, 95% confidence interval [CI] [1.22-2.63], p = 0.003). The quartile with the most negative change in Hb concentration over time (≤-1.00 g/dL) had poorer event-free 2-year survival (HR 1.84, CI [1.13-3.00], p = 0.014).
CONCLUSIONS: Baseline anemia and early postimplantation decline in Hb levels are associated with a worse 2-year prognosis in CRT patients, even though the magnitude of left ventricular reverse remodeling is similar compared to non-anemic patients.

Entities:  

Keywords:  Anemia; Cardiac resynchronization therapy; Heart failure; Prognostic factors; Risk stratification

Mesh:

Substances:

Year:  2015        PMID: 26453528     DOI: 10.1007/s10840-015-0062-9

Source DB:  PubMed          Journal:  J Interv Card Electrophysiol        ISSN: 1383-875X            Impact factor:   1.900


  21 in total

Review 1.  Anemia of chronic disease.

Authors:  Guenter Weiss; Lawrence T Goodnough
Journal:  N Engl J Med       Date:  2005-03-10       Impact factor: 91.245

2.  Heart disease and stroke statistics--2014 update: a report from the American Heart Association.

Authors:  Alan S Go; Dariush Mozaffarian; Véronique L Roger; Emelia J Benjamin; Jarett D Berry; Michael J Blaha; Shifan Dai; Earl S Ford; Caroline S Fox; Sheila Franco; Heather J Fullerton; Cathleen Gillespie; Susan M Hailpern; John A Heit; Virginia J Howard; Mark D Huffman; Suzanne E Judd; Brett M Kissela; Steven J Kittner; Daniel T Lackland; Judith H Lichtman; Lynda D Lisabeth; Rachel H Mackey; David J Magid; Gregory M Marcus; Ariane Marelli; David B Matchar; Darren K McGuire; Emile R Mohler; Claudia S Moy; Michael E Mussolino; Robert W Neumar; Graham Nichol; Dilip K Pandey; Nina P Paynter; Matthew J Reeves; Paul D Sorlie; Joel Stein; Amytis Towfighi; Tanya N Turan; Salim S Virani; Nathan D Wong; Daniel Woo; Melanie B Turner
Journal:  Circulation       Date:  2013-12-18       Impact factor: 29.690

3.  2013 ESC guidelines on cardiac pacing and cardiac resynchronization therapy: the task force on cardiac pacing and resynchronization therapy of the European Society of Cardiology (ESC). Developed in collaboration with the European Heart Rhythm Association (EHRA).

Authors:  Michele Brignole; Angelo Auricchio; Gonzalo Baron-Esquivias; Pierre Bordachar; Giuseppe Boriani; Ole-A Breithardt; John Cleland; Jean-Claude Deharo; Victoria Delgado; Perry M Elliott; Bulent Gorenek; Carsten W Israel; Christophe Leclercq; Cecilia Linde; Lluís Mont; Luigi Padeletti; Richard Sutton; Panos E Vardas
Journal:  Europace       Date:  2013-06-24       Impact factor: 5.214

4.  Heart failure with anemia: novel findings on the roles of renal disease, interleukins, and specific left ventricular remodeling processes.

Authors:  Eileen O'Meara; Jean L Rouleau; Michel White; Karine Roy; Lucie Blondeau; Anique Ducharme; Paul-Eduard Neagoe; Martin G Sirois; Joël Lavoie; Normand Racine; Mark Liszkowski; François Madore; Jean-Claude Tardif; Simon de Denus
Journal:  Circ Heart Fail       Date:  2014-07-15       Impact factor: 8.790

5.  2012 EHRA/HRS expert consensus statement on cardiac resynchronization therapy in heart failure: implant and follow-up recommendations and management.

Authors:  Jean-Claude Daubert; Leslie Saxon; Philip B Adamson; Angelo Auricchio; Ronald D Berger; John F Beshai; Ole Breithard; Michele Brignole; John Cleland; David B Delurgio; Kenneth Dickstein; Derek V Exner; Michael Gold; Richard A Grimm; David L Hayes; Carsten Israel; Christophe Leclercq; Cecilia Linde; Joann Lindenfeld; Bela Merkely; Lluis Mont; Francis Murgatroyd; Frits Prinzen; Samir F Saba; Jerold S Shinbane; Jagmeet Singh; Anthony S Tang; Panos E Vardas; Bruce L Wilkoff; Jose Luis Zamorano
Journal:  Heart Rhythm       Date:  2012-09       Impact factor: 6.343

6.  Anemia is associated with worse symptoms, greater impairment in functional capacity and a significant increase in mortality in patients with advanced heart failure.

Authors:  Tamara B Horwich; Gregg C Fonarow; Michele A Hamilton; W Robb MacLellan; Jeff Borenstein
Journal:  J Am Coll Cardiol       Date:  2002-06-05       Impact factor: 24.094

7.  The effect of cardiac resynchronization on morbidity and mortality in heart failure.

Authors:  John G F Cleland; Jean-Claude Daubert; Erland Erdmann; Nick Freemantle; Daniel Gras; Lukas Kappenberger; Luigi Tavazzi
Journal:  N Engl J Med       Date:  2005-03-07       Impact factor: 91.245

Review 8.  Prevalence of anemia in patients with chronic heart failure and their clinical characteristics.

Authors:  Michel Komajda
Journal:  J Card Fail       Date:  2004-02       Impact factor: 5.712

9.  Clinical correlates and consequences of anemia in a broad spectrum of patients with heart failure: results of the Candesartan in Heart Failure: Assessment of Reduction in Mortality and Morbidity (CHARM) Program.

Authors:  Eileen O'Meara; Tim Clayton; Margaret B McEntegart; John J V McMurray; Chim C Lang; Simon D Roger; James B Young; Scott D Solomon; Christopher B Granger; Jan Ostergren; Bertil Olofsson; Eric L Michelson; Stuart Pocock; Salim Yusuf; Karl Swedberg; Marc A Pfeffer
Journal:  Circulation       Date:  2006-02-13       Impact factor: 29.690

10.  Cardiac resynchronization therapy improves renal function in human heart failure with reduced glomerular filtration rate.

Authors:  Guido Boerrigter; Lisa C Costello-Boerrigter; William T Abraham; Martin G St John Sutton; Denise M Heublein; Kristin M Kruger; Michael R S Hill; Peter A McCullough; John C Burnett
Journal:  J Card Fail       Date:  2008-05-27       Impact factor: 5.712

View more
  2 in total

1.  Echocardiographic Assessment of Right Ventriculo-arterial Coupling: Clinical Correlates and Prognostic Impact in Heart Failure Patients Undergoing Cardiac Resynchronization Therapy.

Authors:  Bruno Bragança; Maria Trêpa; Raquel Santos; Inês Silveira; Marta Fontes-Oliveira; Maria João Sousa; Hipólito Reis; Severo Torres; Mário Santos
Journal:  J Cardiovasc Imaging       Date:  2020-01-21

2.  Prediction of clinical outcome in patients treated with cardiac resynchronization therapy - the role of NT-ProBNP and a combined response score.

Authors:  Z Bakos; N C Chatterjee; C Reitan; J P Singh; R Borgquist
Journal:  BMC Cardiovasc Disord       Date:  2018-04-24       Impact factor: 2.298

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.